with thionyl chloride to give the benzyl chlorides 11, followed by cyanation with potassium cyanide. Treatment of the benzaldehydes 10 with diethyl cyanomethylphosphonate gave the cinnamonitriles 13 which were converted into the 3-phenylpropionitriles 14 by catalytic hydrogenation. Synthesis of the 4-phenylbutyronitriles 16 required a five-step sequence. The Horner-Emmons reaction of the benzaldehydes 10 yielded the cinnamates, which were reduced with diisobutylaluminium hydride (DIBAL-H) to provide the cinnamyl alcohols 15. Catalytic hydrogenation of the intermediates 15 furnished 3-phenylpropanols, which were sequentially treated with phosphorous tribromide and potassium cyanide to yield the desired products 16. Oxidation of the cinnamyl alcohols 15 with activated manganese dioxide gave cinnamoaldehydes, which were transformed into the 5-phenyvaleronitriles 18 via the unsaturated nitriles 17 by the same reactions described for the synthesis of the propionitriles 14. Treatment of the aldehydes 10 under the Wittig reaction conditions with phosphonium ylide generated the intermediates 19. Catalytic hydrogenation of 19 yielded the 6-phenylhexanenitriles 20. The prepared nitriles are listed in Table 2 . The starting 4-alkoxybenzaldehydes 10 were readily prepared by a method described previously. 9f,10) The pyridyl analogues 23, 26, 28 were synthesized as indicated in Chart 4. Coupling of 2-chloro-5-nitropyridine with the corresponding alkoxides gave 2-alkoxy-5-nitropyridines which were reduced by catalytic hydrogenation to obtain 2-alkoxy-5-aminopyridines 21. Diazotization of 21 followed by January 2002 101 Chart 2 treatment with acrylonitrile (Meerwein arylation) gave the 2-bromopropionitriles 22 which were debrominated under catalytic hydrogenation conditions to yield the 3-(6-alkoxy-3-pyridyl)propionitriles 23. The Meerwein arylation of 21 with methyl acrylate gave the 2-bromopropionates 24 which were treated with 1,8-diazabicyclo [5, 4, 0]undec-7-ene (DBU) followed by reduction with DIBAL-H to obtain 3-pyridyl-2-propen-1-ols 25. The w-(6-alkoxy-3-pyridyl)butyro-and valeronitriles 26, 28 were derived from 25 by using the general procedures described in Chart 3. The 2-or 4-functionalized azoles used above were prepared by the procedure reported by Meguro and co-researchers.
Type 2 diabetes is a complex, chronic and metabolic disorder typically characterized by insulin resistance in the liver and peripheral tissues together with a pancreatic b-cell defect. 1) Treatment for type 2 diabetes is currently performed with a combination of exercise and restriction of caloric intake, 2) or drug therapy. The most commonly used oral hypoglycemics for the disease are sulfonylureas. These agents, however, induce serious hypoglycemia 3) and exhibit primary or secondary failure, which is presumably due to their characteristics as insulin secretagogues. Thus, use of the non-sulfonylurea class of hypoglycemics which do not increase insulin secretion but enhance the action of insulin (insulin sensitizers) is required. 4) In the course of developing novel therapeutic agents for the treatment of type 2 diabetes, we discovered the prototypical 2,4-thiazolidinedione compound, ciglitazone (1) 5) (Chart 1), which has antihyperglycemic activity in two insulin-resistant animal models, KKA y mice 6) and Wistar fatty rats, 7) but does not show the effect in type 1 diabetic or nondiabetic animals. 8) Efforts to find more potent antidiabetic 5-benzyl-2,4-thiazolidinedione derivatives 9) resulted in the discovery of pioglitazone (2) 9b-f) (Chart 1), which has a 2-(5-ethyl-2-pyridyl)ethoxy group at the p-position of the 5-benzyl substituent and is currently in clinical use. After that, we identified a series of potent 5-benzyl-2,4-thiazolidinediones with a 4-linked oxazole or thiazole moiety, leading to the discovery of AD-5061 (3) and AD-5075 (4) (Chart 1) as optimized analogues within the azole series. 10) Since our discovery of ciglitazone, a substantial effort has been made in the pharmaceutical industry to develop new types of drugs for type 2 diabetes, particularly insulin sensitizers possessing 2,4-thiazolidinedione 11) or analogous acidic 5-membered heterocycles.
12) A series of perfluoroamides represented by Wy-49,322 (5) (Chart 1) was the first hypoglycemic agent having a tetrazole ring as an acidic heterocycle.
12a) It appeared, however, that the lipophilic perfluorocarbon chain was the component critical for the activity, and unfavorable side-effects prohibited further development of these compounds. 13) We describe in this paper the syntheses and biological activities of a series of 5-substituted-1H-tetrazoles, including the finding that use of a tri-or tetramethylene unit as a spacer between the tetrazole and the phenyl or pyridyl moiety is better than that of the methylene group which was previously considered as the optimal spacer for use in the series of 2,4-thiazolidinediones.
Chemistry
Most of the 5-substituted-1H-tetrazoles 8, 9 in Table 1 were synthesized from the corresponding nitriles 6, 7 as shown in Chart 2. Conversion of the nitriles into final products was carried out in N,N-dimethylformamide (DMF) by treatment with sodium azide and ammonium chloride (method A). Some of the 5-alkyl-1H-tetrazoles 8 were obtained from the 5-alkenyl-1H-tetrazoles 9 by catalytic hydrogenation (method B).
The requisite nitriles were prepared as shown in Chart 3. The alkoxyphenylacetonitriles 12 were obtained starting with the corresponding benzaldehydes 10 via a three-step sequence: reduction with sodium borohydride and chlorination with thionyl chloride to give the benzyl chlorides 11, followed by cyanation with potassium cyanide. Treatment of the benzaldehydes 10 with diethyl cyanomethylphosphonate gave the cinnamonitriles 13 which were converted into the 3-phenylpropionitriles 14 by catalytic hydrogenation. Synthesis of the 4-phenylbutyronitriles 16 required a five-step sequence. The Horner-Emmons reaction of the benzaldehydes 10 yielded the cinnamates, which were reduced with diisobutylaluminium hydride (DIBAL-H) to provide the cinnamyl alcohols 15. Catalytic hydrogenation of the intermediates 15 furnished 3-phenylpropanols, which were sequentially treated with phosphorous tribromide and potassium cyanide to yield the desired products 16. Oxidation of the cinnamyl alcohols 15 with activated manganese dioxide gave cinnamoaldehydes, which were transformed into the 5-phenyvaleronitriles 18 via the unsaturated nitriles 17 by the same reactions described for the synthesis of the propionitriles 14. Treatment of the aldehydes 10 under the Wittig reaction conditions with phosphonium ylide generated the intermediates 19. Catalytic hydrogenation of 19 yielded the 6-phenylhexanenitriles 20. The prepared nitriles are listed in Table 2 .
The starting 4-alkoxybenzaldehydes 10 were readily prepared by a method described previously.
9f, 10) The pyridyl analogues 23, 26, 28 were synthesized as indicated in Chart 4. Coupling of 2-chloro-5-nitropyridine with the corresponding alkoxides gave 2-alkoxy-5-nitropyridines which were reduced by catalytic hydrogenation to obtain 2-alkoxy-5-aminopyridines 21. Diazotization of 21 followed by Chart 2 treatment with acrylonitrile (Meerwein arylation) gave the 2-bromopropionitriles 22 which were debrominated under catalytic hydrogenation conditions to yield the 3-(6-alkoxy-3-pyridyl)propionitriles 23. The Meerwein arylation of 21 with methyl acrylate gave the 2-bromopropionates 24 which were treated with 1,8-diazabicyclo [5, 4, 0] undec-7-ene (DBU) followed by reduction with DIBAL-H to obtain 3-pyridyl-2-propen-1-ols 25. The w-(6-alkoxy-3-pyridyl)butyro-and valeronitriles 26, 28 were derived from 25 by using the general procedures described in Chart 3. The 2-or 4-functionalized azoles used above were prepared by the procedure reported by Meguro and co-researchers.
14)

Biology
In Vitro. Peroxisome Proliferator-Activated Receptor g g (PPARg g)-Retinoid X Receptor a a (RXRa a) Heterodimer Transactivation Assay PPARg : RXRa : PPREϫ4/CHO-K1 cells were cultured in HAM F12 medium (Nissui Seiyaku, Japan) containing 10% fetal bovine serum (Life Technologies, Inc., U.S.A.) and then inoculated into a 96-well white plate (Corning Coaster Corporation, U.S.A.) at a density of 2ϫ10 4 cells/well, and cultured in a carbonate gas incubator at 37°C overnight. After the washing of the white plate with PBS (phosphate-buffered saline), 90 ml of HAM F12 medium containing 0.1% fatty acid-free bovine serum albumin (BSA) and 10 ml of the test substance were added to the plate, which was then cultured in a carbonate gas incubator at 37°C for 48 h. After removal of the medium, 40 ml of PICAGENE 7.5 (Wako Pure Chemical Ind., Osaka, Japan) was added, and after stirring, luciferase activity was determined using Lumistar (BMG Labtechnologies GmBH, Germany). A fold induction was calculated based on the luciferase activity of each test substance with the luciferase activity in the non-treatment group being regarded as 1. The values of the test substance concentration and the fold induction were analyzed using PRISM 2.01 (GraphPad Software Inc., U.S.A.) to calculate the EC 50 , the effective concentration of a compound for the induction of 50% of maximum activity.
In Vivo The glucose and lipid lowering activities of the compounds prepared were tested using KKA y mice 6) and Wistar fatty rats. 7) KKA y Mice (9-13 Weeks Old): After being fed a powdered laboratory chow (CE-2, Clea Japan Inc., Tokyo, Japan) for 3 d, the mice were divided into experimental groups of five animals each based on their blood glucose levels. The test compounds were given as a dietary admixture at 0.01, 0.005, or 0.001% in the diet. The mice were fed the experimental diet and water ad libitum for 4 d. Blood samples were taken from the orbital vein. The plasma glucose and plasma triglyceride levels were determined by enzyme methods using the Iatrochem-GLU(A) and Iatro-MA701 TG kits (Iatron Laboratories, Inc., Tokyo, Japan), respectively. The respective values are shown as percent reduction from the control value. The effective dose to reduce plasma glucose and triglyceride levels by 25% (ED 25 ) was determined using results of an experiment in which three different doses were tested. The doses were selected in accordance with the potency of the compound. The dosages of test compounds (mg · kg Ϫ1 · d 
149-151
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106-107 The rats were divided into experimental groups of five animals each based on their plasma glucose and triglyceride levels. They were orally administered the compounds suspended in 0.5% methyl cellulose (Wako Pure Chemical Ind., Osaka, Japan) at three different concentrations once per day for 6 d via a stomach tube. They were fed a CE-2 pellet diet and water ad libitum. Blood samples were taken from a tail vein. Plasma glucose and triglyceride levels were measured and the ED 25 was estimated in the same fashion as described above.
Results and Discussion
Antidiabetic activities were initially determined for KKA y mice. As noted in our previous paper on the 5-(4-alkoxybenzyl)-2,4-thiazolidinedione series of compounds, two-carbon units between the azole ring and oxygen atom at the 4-position of the benzyl group were the most effective in eliciting the biological activity. 10) Based on this finding, we began our study with 5-alkyl-1H-tetrazoles possessing a 4-[2-(4-oxazolyl)ethoxy]phenyl moiety at the w-position of the 5-alkyl chain, and found that compound 31 (Table 3) had glucose lowering activity. Structure-activity relationship (SAR) studies on the 5-substituted-1H-tetrazoles related to 31 initially focused on the length of the carbon chain between the tetrazole ring and the benzene ring. Studies of variation of the polymethylene unit [(CH 2 ) n : nϭ1 -4] showed that ethylene (nϭ2) was the best spacer (31 vs. 30, 32, 33). Derivative 34 with an unsaturated two-carbon unit was less potent than the corresponding saturated compound 31. With regard to the effect of a substituent at the 2-position of the oxazole ring, an alkyl group was inferior to an aryl or a heteroaryl group (35, 36 vs. 31, 39), as was also the case for the 2,4-thiazolidinedione derivatives.
10) Introduction of a substituent into the benzene ring at the 2-position of the oxazole ring of 31 resulted in a decrease in activity (31 vs. 37, 38). As regards the central benzene ring, conversion into the pyridine ring reduced the antihyperglycemic activity (31 vs. 40). Thus, considerable activity was observed for compounds with a 2-(4-oxazolyl)ethoxy moiety (31-33, 36, 37, 39, 40), but these tetrazole derivatives were less active than pioglitazone 2. We found that antidiabetic activity was increased by extending the spacer between the tetrazole ring and the benzene ring from methylene (30: -(CH 2 )-) to ethylene (31: -(CH 2 ) 2 -).
Considering the effect of the distance between the oxazole 104 Vol. 50, No. 1 a) Maximum reductions in plasma glucose and plasma triglyceride levels at a dosage of 0.001, 0.005 or 0.01% in the diet were calculated as percent reduction with respect to the control value. b) Effective dose (mg · kg Ϫ1 · d Ϫ1 ) for 25% reduction, estimated from a dose-response curve for three doses. c) Less than 20% reduction at this dosage. d) Statistically significant at ( * ) pϽ0.05, ( * * ) pϽ0.01 by Dunnett's test. e) Compound was given as a dietary admixture at 0.02% in the diet. and the tetrazole moieties on activity, our attention was next directed toward a series of compounds with a (4-oxazolyl)-methoxy moiety (41-58). These derivatives, especially those with a tri-or tetramethylene moiety as the spacer between the central benzene ring and the tetrazole ring (43, 44, 47-49, 52, 53), demonstrated much more activity than the abovementioned compounds with a 2-(4-oxazolyl)ethoxy moiety. However, compound 46 with an unsaturated carbon chain as the spacer between the central benzene ring and the tetrazole ring was less active than the corresponding saturated compound 44. Exchange of both alkyl spacers on the central benzene ring in compound 43 (-CH 2 -, -(CH 2 ) 3 -) resulted in compound 29 with less potent activity. Altering the substitution pattern on the benzene ring also resulted in compounds with less antidiabetic activity (44 vs. 56, 57). These findings suggested that the spatial configuration of three aromatic rings (oxazole, central benzene, tetrazole) connected by two alkyl spacers (-(CH 2 ) n -and Z (Table 1) ) plays an important role in determining activity. Derivatives with a 2-naphthyl, 2-furyl, or 2-benzofuranyl group at the 2-position of the oxazole ring were equipotent to the 2-phenyl derivative (47-49 vs. 43). Substitution of a thiazole or a triazole for the oxazole ring, or shifting the side chain from the 4-to the 2-position of the oxazole ring, significantly reduced potency (43 vs. 54, 55; 44 vs. 58). These findings contrast with our previous results for the 2,4-thiazolidinediones, 10) for which no significant difference was observed between the activities of the oxazole and thiazole derivatives, and of the 4-oxazolyl-and 2-oxazolyl derivatives. Introduction of an additional substituent into the central benzene ring also resulted in compounds with less antidiabetic activity (44 vs. 50, 51). The pyridyl analogues had activities either stronger than or comparable to those of the parent compounds (43 vs. 52; 44 vs. 53). In particular, compound 52 (ED 25 ϭ0.0839 mg · kg
) exhibited an approximately 70-fold increase in antihyperglycemic activity over pioglitazone hydrochloride (2:
). 9b) These findings were quite different from the result of compound 40 with a 2-(4-oxazolyl)ethoxy moiety on the central pyridine ring as discussed above. These results confirmed us that the spatial configuration of three aromatic rings (oxazole, central benzene (central pyridine), tetrazole) is very important to appear the potent activity and the pyridine ring, especially, among three aromatic rings plays the most crucial role in increasing antidiabetic effect. Wy-49,322 (5), 12a) reported as a novel hypoglycemic tetrazole derivative, was less potent than the typical tetrazoles (43, 52) in this model.
A number of potent analogues, 43, 44, 52, and 53, were tested for their glucose and lipid lowering activities in Wistar fatty rats. 7) As shown in Table 4 , SARs for these compounds were almost the same as those in KKA y mice. The pyridyl analogue 52 had the most potent glucose lowering activity (ED 25 ϭ0.0873 mg · kg
, and was about 5 times more active than pioglitazone hydrochloride (2, ED 25 ϭ0.5 mg · kg
). 9d) Moreover, these compounds were also evaluated in the transactivation assay of PPARg as shown in Table  4 . A correlation between the in vitro transcriptional activity of PPARg and the in vivo glucose lowering activity in two genetically obese and diabetic animal models, KKA y mice and Wistar fatty rats, was demonstrated as expected. 15) In summary, we showed that a series of 5-substituted-1H-tetrazoles had potent antidiabetic activities in KKA y mice and Wistar fatty rats, that were genetically obese and diabetic animal models. The tetrazole moiety suitably functioned as a bioisostere for the acidic 2,4-thiazolidinedione ring. The results of the SAR studies identified that the spatial configuration of three aromatic rings (oxazole, central benzene, tetrazole) connected by two alkyl spacers plays an important role in determining the activity. Compound 52, the most potent derivative in this series, and some of its congeners, enhanced the remarkable PPARg transcriptional activity, suggesting that this series of compounds act via the same mechanism reported for 2,4-thiazolidinedione-type insulin sensitizers.
Experimental
All melting points were determined on a Yanagimoto micro melting point apparatus, and are uncorrected. The 
General Procedure for Method B. 5-[2-[4-(5-Methyl-2-phenyl-4-oxazolylmethoxy)phenyl]ethyl]-1H-tetrazole (42) A mixture of 5-[2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]vinyl]-1H
-tetrazole (59, 1.00 g, 2.8 mmol), 5% Pd-C (50% wet, 0.50 g), and 1,4-dioxane (100 ml) was hydrogenated at 1 atm. After removal of the catalyst by filtration and the filtrate was concentrated in vacuo to give the title compound (42, 810 mg, 81% Thionyl chloride (3.1 g, 26 mmol) was added to a stirred solution of 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl alcohol (6.8 g, 22 mmol) in CHCl 3 (100 ml). After stirring for 1 h, the reaction mixture was washed successively with aqueous sodium bicarbonate and brine. The organic layer was separated, dried (MgSO 4 ), and concentrated to give the title compound (11a, 6.5 g, 79%). mp 93-94°C (AcOEt-hexane). Methyl-2-phenyl-4-oxazolyl)ethoxy]phenylacetonitrile (12a) A mixture of 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl chloride (11a, 6.4 g, 20 mmol), potassium cyanide (4.0 g, 61 mmol), and DMF (50 ml) was stirred at 60°C for 2 h. The reaction mixture was poured into water and extracted with AcOEt. The extract was washed with brine, dried (MgSO 4 ), and concentrated in vacuo to give the title compound (12a, 5.2 g, 81%). DIBAL-H (1.5 M in toluene, 16 ml, 24 mmol) was added dropwise to a stirred and ice-cooled solution of ethyl (E)-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)cinnamate (4.4 g, 12 mmol) in CH 2 Cl 2 (80 ml). After stirring for 1 h, 2 N HCl (50 ml) was added to the mixture with cooling, and then the resultant was stirred at room temperature for 1 h. The organic layer was separated, dried (MgSO 4 ), and concentrated in vacuo to give the title compound (15b, 3.8 g, 93% A solution of 4-(2-fluoro-4-nitrophenoxymethyl)-5-methyl-2-phenyloxazole (13.6 g, 41.4 mmol) in THF (200 ml) was hydrogenated on 5% Pd-C (50% wet, 2.00 g) at 1 atm. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo to give 3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)aniline (12.3 g, quant.) 2H, m) .
4-[2-(5-
A solution of sodium nitrite (3.13 g, 45.4 mmol) in water (5 ml) was added dropwise to a stirred and ice-cooled mixture of 3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)aniline (12.3 g, 41.2 mmol), hydrobromic acid (47%, 28.4 g, 164 mmol), MeOH (50 ml), and acetone (150 ml) below 5°C. After stirring for 15 min, methyl acrylate (21.3 g, 247 mmol) was added and the temperature was raised to 35°C. Powdered copper(I) oxide (50 mg) was added gradually to the vigorously stirred mixture. After a nitrogen gas evolution had ceased, the reaction mixture was concentrated in vacuo. The residue was diluted with ammonia solution (25% in water) and extracted with AcOEt. The extract was washed with water, dried (MgSO 4 ), and concentrated to leave an oil which was purified by column chromatography on 3 mmol), 5% Pd-C (50% wet, 500 mg), and 1,4-dioxane (50 ml) was hydrogenated at 1 atm. After removal of the catalyst by filtration, the filtrate was concentrated in vacuo to give 3-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propan-1-ol (2.8 g, 93%). mp 72-73°C (AcOEt-hexane). 
